CXCL11 and atherosclerosis: Importantly, by sparing peripheral cells—including peripheral, non‐CNS endothelial cells—gene therapy with the AAV‐BR1 vector obviates potential adverse effects that have been attributed to NEMO, such as promoting atherosclerosis (Gareus et al, 2008).